Brean Murray Initiates Coverage on NPS Pharmaceuticals (NPSP) with a Buy
More News related to NPSP
- NPS Pharma (NPSP) Reports Q3 Loss of $0.16, Misses by 4c
- NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- NPS Pharmaceuticals to Report Third Quarter Financial Results on November 4, 2009
- Data Demonstrate That GATTEX(TM) (Teduglutide) Improves Lean Body Mass, Mineral Composition and Electrolyte Levels in Patients with Parenteral Nutrition Dependent Short Bowel Syndrome
Brean Murray initiates coverage on NPS Pharmaceuticals (Nasdaq: NPSP) with a Buy. Price target $11.
Brean analyst says, "With the current market value of the company below the value of the royalties from Sensipar and Regpara, we believe that NPSP's stock is significantly undervalued and is well poised to generate significant upside, driven by potential positive data for two pivotal Phase III trials, Gattex in short bowel syndrome and NPSP558 in hypoparathyroidism in 2H10."
To see more analyst ratings on NPSP Click Here.
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders.
Related Categories
New CoverageStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
